AIKI vs. XELB, BIAF, DKDCA, FOXO, ISPC, FNJN, REFR, ACTG, IQV, and ICLR
Should you be buying AIkido Pharma stock or one of its competitors? The main competitors of AIkido Pharma include Xcel Brands (XELB), bioAffinity Technologies (BIAF), Data Knights Acquisition (DKDCA), FOXO Technologies (FOXO), iSpecimen (ISPC), Finjan (FNJN), Research Frontiers (REFR), Acacia Research (ACTG), IQVIA (IQV), and ICON Public (ICLR).
AIkido Pharma (NASDAQ:AIKI) and Xcel Brands (NASDAQ:XELB) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their earnings, risk, media sentiment, valuation, dividends, profitability, analyst recommendations, institutional ownership and community ranking.
Xcel Brands received 133 more outperform votes than AIkido Pharma when rated by MarketBeat users. However, 63.92% of users gave AIkido Pharma an outperform vote while only 49.68% of users gave Xcel Brands an outperform vote.
AIkido Pharma has a net margin of 0.00% compared to Xcel Brands' net margin of -156.27%. AIkido Pharma's return on equity of -18.21% beat Xcel Brands' return on equity.
AIkido Pharma has a beta of 0.93, indicating that its stock price is 7% less volatile than the S&P 500. Comparatively, Xcel Brands has a beta of 1.47, indicating that its stock price is 47% more volatile than the S&P 500.
In the previous week, Xcel Brands had 4 more articles in the media than AIkido Pharma. MarketBeat recorded 4 mentions for Xcel Brands and 0 mentions for AIkido Pharma. Xcel Brands' average media sentiment score of 0.93 beat AIkido Pharma's score of 0.00 indicating that Xcel Brands is being referred to more favorably in the news media.
10.9% of AIkido Pharma shares are owned by institutional investors. Comparatively, 18.6% of Xcel Brands shares are owned by institutional investors. 8.6% of AIkido Pharma shares are owned by company insiders. Comparatively, 52.4% of Xcel Brands shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.
AIkido Pharma has higher earnings, but lower revenue than Xcel Brands. Xcel Brands is trading at a lower price-to-earnings ratio than AIkido Pharma, indicating that it is currently the more affordable of the two stocks.
Summary
Xcel Brands beats AIkido Pharma on 9 of the 15 factors compared between the two stocks.
Get AIkido Pharma News Delivered to You Automatically
Sign up to receive the latest news and ratings for AIKI and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding AIKI and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
AIkido Pharma Competitors List
Related Companies and Tools
